Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product.".
Press Release Jul 04 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Aurobindo Pharma
- Press Release Jun 23 2023
- Press Release May 27 2023
- Press Release May 26 2023
- Press Release Mar 30 2023
- Press Release Mar 08 2023
Later from Aurobindo Pharma
- Press Release Jul 12 2023
- Press Release Jul 25 2023
- Press Release Aug 01 2023
- Aurobindo Pharma Ltd Press Release Aug 07 2023
- Annual CSR Report 2022-23
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma